Is this your brand? Sign in to claim ownership.
Sign in to claim this brandLuminex Corporation
US
Last updated September 17, 2026
About
Diasorin is the global leader in Molecular Diagnostics and Immunodiagnostics market. Discover all Diasorin’s diagnostic solutions.
From the manufacturer's own website. Source
What Luminex Corporation makes
Luminex Corporation manufactures multiplex analysers for laboratory use, including systems like the LIAISON PLEX Chassis and FLEXMAP 3D, which support nucleic acid testing and microarray-based diagnostics. Their product portfolio includes kits for detecting bloodstream pathogens, gastrointestinal pathogens, and respiratory viruses, such as the LIAISON PLEX Gastrointestinal Flex Assay and RP Flex Amplification Tray. The company also supplies reagents for internal controls, viral targets like CMV and BKV, and specialized components like extraction trays and calibration kits for Clostridium difficile and Candida glabrata testing.
These devices are regulated under FDA pathways, including 510(k) clearances and de novo submissions, with classifications spanning Class I and Class II. The products are listed in the FDA’s 510(k) and UDI registries, reflecting their compliance with U.S. medical device regulations. Luminex Corporation is headquartered in the United States.
Written from this company's registered devices by an AI model, and not verified by a human reviewer.
Information
- Country
- US
- Address
- 12212 Technology Blvd, AUSTIN, TX, 78727
- Website
- int.diasorin.com/en
- it.linkedin.com/company/diasorin
- facebook.com/diasorin
- —
- Phone
- —
- PRRC Contact
- —
- EUDAMED SRN
- —
- FDA FEI Number
- 3002524000
- DUNS Number
- —
Catalogue (125)
Page 1 of 3Related Companies
Authorised Representatives
No authorised representatives on record.
Importers
Not available yet.
Notified Bodies
Not available yet.
Authorities
Not available yet.
FDA Recalls (40)
Recalls reported by this firm to the FDA. Listed at company level — FDA recall records don't identify a specific catalogue device.
Luminex Corporation has 40 FDA recall records initiated between May 24, 2011, and April 16, 2025. The records reflect various statuses, including completed, open, classified, and terminated. Recalled items primarily involve diagnostic test cartridges, instruments, and components, with reasons citing potential false negative or positive results, instrument malfunctions, labeling errors, and defects in calibration tools. Issues include barcode scanner errors, reagent failures, and leaks affecting test accuracy, as well as unapproved or improperly validated field service equipment.
AI-generated summary of the recall records listed below. It describes what the records state and is not an assessment of this manufacturer.
| Date | Recall No. | Class | Status | Reason |
|---|---|---|---|---|
| Apr 16, 2025 | Z-1903-2025 | — | completed | It was determined that the consumable issue may result in No Call - INT CTL 1 and/or False Negative results on a small portion of the lot of test cartridges. |
| Jun 20, 2024 | Z-2533-2024 | — | open, classified | Potential for defective test cartridges which may result in false positive results for the Staphylococcus lugdunensis and Enterococcus faecium targets. |
| Nov 7, 2023 | Z-0500-2024 | — | open, classified | Potentially defective utility trays in the reagent kits. |
| Jun 5, 2023 | Z-2023-2023 | — | open, classified | It is possible that in rare instances the VERIGENE CDF Nucleic Acid Test Kit (Part No. 20-005-022) and the VERIGENE Enteric Pathogens Nucleic Acid Test Kit (Part No. 20-005-023) could provide a false-negative result due to hydrophobic characteristics in specific FLOQSwab lots. |
| Jun 5, 2023 | Z-2024-2023 | — | open, classified | It is possible that in rare instances the VERIGENE CDF Nucleic Acid Test Kit (Part No. 20-005-022) and the VERIGENE Enteric Pathogens Nucleic Acid Test Kit (Part No. 20-005-023) could provide a false-negative result due to hydrophobic characteristics in specific FLOQSwab lots. |
| Sep 14, 2022 | Z-0134-2023 | — | open, classified | A part defect with the wash 1 syringe of an SARS-CoV-2 assay could lead to incomplete extraction thereby producing an invalid or false negative assay result. |
| Jul 14, 2022 | Z-1524-2022 | — | open, classified | SARS-CoV-2 assay that detects SARS-CoV-2 ORF1ab and N genes may not detect the ORF1ab gene. A positive results if either SARS-CoV-2 genes is detected, but If both genes are mistakenly not detected, a false negative result would be generated. |
| Jun 17, 2022 | Z-1335-2022 | — | open, classified | There is a potential for false negative results using VERIGENE CDF Stool PREP KIT and VERIGENE EP Stool PREP KIT due to hydrophobic characteristics of the swab. |
| Jun 17, 2022 | Z-1334-2022 | — | open, classified | There is a potential for false negative results using VERIGENE CDF Stool PREP KIT and VERIGENE EP Stool PREP KIT due to hydrophobic characteristics of the swab. |
| Apr 5, 2022 | Z-1092-2022 | — | open, classified | Heater within the Verigene System may be outside of established temperature limits for assays which could result in false negative results. |
| Feb 15, 2022 | Z-1109-2022 | — | open, classified | Higher than normal "No Call Internal Control failures" due to a missing reagent within a small subset of the extraction tray lot. |
| Nov 17, 2021 | Z-0553-2022 | — | terminated | Impacted lot may leak inside the ARIES instrument. Testing confirmed a leak rate of 0.9%. Leaking cassettes could potentially lead to incorrect results or a delay in reporting results due to an Invalid. |
| Aug 3, 2021 | Z-2451-2021 | — | open, classified | There is potential for false positive results. |
| Apr 16, 2021 | Z-0498-2022 | — | terminated | Impacted lot may leak inside the ARIES instrument. |
| Mar 18, 2021 | Z-1488-2021 | — | open, classified | Potential for a false-negative result for Vibrio parahaemolyticus, Salmonella, and/or Shigella spp when used with the VERIGENE Enteric Pathogens Nucleic Acid Test Kit. |
| Oct 30, 2020 | Z-2008-2021 | — | open, classified | Potential for a false-negative result. |
| Oct 30, 2020 | Z-2009-2021 | — | open, classified | Potential for a false-negative result. |
| Oct 30, 2020 | Z-2007-2021 | — | open, classified | Potential for a false-negative result. |
| Oct 30, 2020 | Z-2010-2021 | — | open, classified | Potential for a false-negative result. |
| Oct 30, 2020 | Z-2011-2021 | — | open, classified | Potential for a false-negative result. |
| Oct 30, 2020 | Z-2006-2021 | — | open, classified | Potential for a false-negative result. |
| Oct 13, 2020 | Z-0476-2021 | — | terminated | Luminex has determined that three (3) separate test fixtures used by field service engineers to service the VERIGENE SP Processors were procured from unapproved sources and, in some cases, were manufactured using unvalidated processes. These text fixtures were used to calibrate and verify VERIGENESP devices. |
| Oct 13, 2020 | Z-0477-2021 | — | terminated | Luminex has determined that three (3) separate test fixtures used by field service engineers to service the VERIGENE SP Processors were procured from unapproved sources and, in some cases, were manufactured using unvalidated processes. These text fixtures were used to calibrate and verify VERIGENE SP devices. |
| Jun 15, 2020 | Z-2775-2020 | — | terminated | An instrument failure mode that may result in a Blood Culture Gram Positive (BC-GP) or Gram Negative (BC-GN) false negative call. |
| Jun 15, 2020 | Z-2776-2020 | — | terminated | An instrument failure mode that may result in a Blood Culture Gram Positive (BC-GP) or Gram Negative (BC-GN) false negative call. |
| Apr 22, 2019 | Z-0920-2022 | — | open, classified | Two of three complaints were initiated due to the customers repeatedly obtaining No Call results on the Processor SPs in question. |
| Feb 20, 2019 | Z-2287-2019 | — | open, classified | Through internal investigation, it was discovered that a portion of side cassette assemblies (SCAs) back side seal (BSS) did not meet design specification, resulting in partially sealed SCAs. The impact of a partial seal of the BSS could result in potential decrease of volume for each solution in the SCAs and decreased sensitivity or stability of the assay. |
| Feb 20, 2019 | Z-2282-2019 | — | open, classified | Through internal investigation, it was discovered that a portion of side cassette assemblies (SCAs) back side seal (BSS) did not meet design specification, resulting in partially sealed SCAs. The impact of a partial seal of the BSS could result in potential decrease of volume for each solution in the SCAs and decreased sensitivity or stability of the assay. |
| Feb 20, 2019 | Z-2286-2019 | — | open, classified | Through internal investigation, it was discovered that a portion of side cassette assemblies (SCAs) back side seal (BSS) did not meet design specification, resulting in partially sealed SCAs. The impact of a partial seal of the BSS could result in potential decrease of volume for each solution in the SCAs and decreased sensitivity or stability of the assay. |
| Feb 20, 2019 | Z-2288-2019 | — | open, classified | Through internal investigation, it was discovered that a portion of side cassette assemblies (SCAs) back side seal (BSS) did not meet design specification, resulting in partially sealed SCAs. The impact of a partial seal of the BSS could result in potential decrease of volume for each solution in the SCAs and decreased sensitivity or stability of the assay. |
| Feb 20, 2019 | Z-2283-2019 | — | open, classified | Through internal investigation, it was discovered that a portion of side cassette assemblies (SCAs) back side seal (BSS) did not meet design specification, resulting in partially sealed SCAs. The impact of a partial seal of the BSS could result in potential decrease of volume for each solution in the SCAs and decreased sensitivity or stability of the assay. |
| Feb 20, 2019 | Z-2285-2019 | — | open, classified | Through internal investigation, it was discovered that a portion of side cassette assemblies (SCAs) back side seal (BSS) did not meet design specification, resulting in partially sealed SCAs. The impact of a partial seal of the BSS could result in potential decrease of volume for each solution in the SCAs and decreased sensitivity or stability of the assay. |
| Feb 20, 2019 | Z-2284-2019 | — | open, classified | Through internal investigation, it was discovered that a portion of side cassette assemblies (SCAs) back side seal (BSS) did not meet design specification, resulting in partially sealed SCAs. The impact of a partial seal of the BSS could result in potential decrease of volume for each solution in the SCAs and decreased sensitivity or stability of the assay. |
| Dec 26, 2018 | Z-0822-2019 | — | terminated | On lot of VERIGENE(R) BC-GP Utility Kits (20-011-018) were labeled with the VERIGENE(R) Amplification Tray label. |
| Dec 10, 2018 | Z-0054-2021 | — | open, classified | No results/incorrect results due to failure of the hybridization heater. |
| Sep 14, 2018 | Z-0445-2019 | — | terminated | Potential to lead to a false negative results. |
| Jun 29, 2018 | Z-2292-2019 | — | terminated | An incorrect control board and firmware installed in some of the Hand Held Barcode Scanners could result in sample/patient mismatch or duplicate results (from other patients specimens) for a patient order. |
| May 8, 2018 | Z-2952-2018 | — | terminated | Elevated false positive results Yersinia enterocolitica (Yersinia) from customers using the EP Nucleic Acid Test Cartridges component (20-006-023) from the Verigene EP Nucleic Acid Test Kit (20-005-023). |
| Apr 19, 2017 | Z-2094-2017 | — | terminated | The hand-held barcode scanner that is used as an accessory to enter ARIES cassette and specimen identifications on the ARIES Systems populates patient sample IDs with a previously scanned sample ID when entering orders into an ARIES instrument. |
| May 24, 2011 | Z-3112-2011 | — | terminated | Inaccurate test results, due to possible defective primers, which could lead to incorrect dosage on manufactured drug assays. |